ALKS Q1 2020 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$246M+10.4% YoY

Gross Profit

$199M80.8% margin

Operating Income

-$37M-15.2% margin

Net Income

-$39M-15.7% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-40.3%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$60M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$763M

Stockholders' Equity

$1.1B

Cash & Equivalents

$176M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$246M	$223M	+10.4%
Gross Profit	$199M	$178M	+12.0%
Operating Income	-$37M	-$76M	+50.8%
Net Income	-$39M	-$96M	+59.9%

Revenue Segments

Product

$130M50%

Vivitrol

$79M30%

Aristada Or Aristada Initio

$51M20%